Wan Amir-Jeffery Bin Wan Abdul Majid

Chief Executive Officer - Group Operations

Date of Appointment to Current Position
21 October 2024

52

M

Back

Directorship in Other Public Companies and Other Listed Entities:

None

Family Relationship with Any Director and/or Major Shareholder:

None

Conflict of Interest or Potential Conflict of Interest, Including Interest in Any Competing Business with the Company or Its Subsidiaries:

None

List of Convictions for Offences within the Past 5 Years and Particulars of Any Public Sanction or Penalty Imposed by the Relevant Regulatory Bodies during the Financial Year:

None

Details of Any Interest in the Securities of the Company or Its Subsidiaries:

None

Academic/Professional Qualification/Membership(s):

  • Bachelor of Business Administration – International Trade, University of Central Arkansas, United States of America
  • Senior Management Development Program, Harvard Business School, United States of America
  • Qualified Risk Director (QRD) programme
  • Member of the Institute of Corporate Directors Malaysia (ICDM)
Back

Past Appointments/Experiences:

  • Executive Director, Resources Management (SRM) Sdn Bhd from 1997 to 2007
  • Lead Business Analyst, Biomedical Business Development and Investment Division, Malaysian Biotechnology Corporation (BiotechCorp) Sdn Bhd from 2007 to 2008
  • Vice President, Biomedical Business Development and Investment Division, Malaysian Biotechnology Corporation (BiotechCorp) Sdn Bhd from 2008 to 2013
  • Chief Executive Officer, Johor Biotechnology & Biodiversity Corporation and J-Biotech Holdings Sdn. Bhd from 2013 to 2016
  • Chief Strategy Officer, Duopharma Biotech Berhad from 2016 to 2018
  • Chief Operating Officer, Duopharma Biotech Berhad from 2018 to 2020
  • Chief Commercial Officer, Duopharma Biotech Berhad from 2020 to 2022
  • Chief Executive Officer – Commercial, Duopharma Biotech Berhad from 2022 to 2024

Other Current Appointment(s):

  • Member of Duopharma Biotech’s Group Management Committee
  • Member of the Executive Council of the Malaysian Organisation of Pharmaceutical Industries (MOPI)
  • INTI University Advisory Board Member

Notes:

  • Redesignated to current position on 21 October 2024.

  • Previously served as Chief Executive Officer – Commercial from 2022 to 2024.

Back